1. Home
  2. MG vs TRDA Comparison

MG vs TRDA Comparison

Compare MG & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mistras Group Inc

MG

Mistras Group Inc

HOLD

Current Price

$14.19

Market Cap

424.6M

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$11.77

Market Cap

404.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MG
TRDA
Founded
1978
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
424.6M
404.4M
IPO Year
2009
2021

Fundamental Metrics

Financial Performance
Metric
MG
TRDA
Price
$14.19
$11.77
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$20.00
AVG Volume (30 Days)
185.1K
247.9K
Earning Date
03-04-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
60.33
N/A
EPS
0.57
N/A
Revenue
$715,300,000.00
$61,520,000.00
Revenue This Year
$1.51
N/A
Revenue Next Year
$3.30
$3.14
P/E Ratio
$24.37
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.06
$4.93
52 Week High
$14.70
$14.27

Technical Indicators

Market Signals
Indicator
MG
TRDA
Relative Strength Index (RSI) 60.87 62.28
Support Level $13.72 $10.52
Resistance Level $14.45 $11.56
Average True Range (ATR) 0.41 0.76
MACD -0.07 0.05
Stochastic Oscillator 64.74 84.21

Price Performance

Historical Comparison
MG
TRDA

About MG Mistras Group Inc

MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: